Integrated tissue transcriptome deconvolution of grade-associated tumor microenvironment patterns in CNS tumors.
Abstract
e14039 Background: Central nervous system (CNS) tumors exhibit marked tumor microenvironment (TME) heterogeneity, including immune exclusion and immunosuppression that may limit benefit from immunotherapy. We applied an integrated tissue transcriptome-based framework to define clinically relevant TME patterns associated with tumor grade. Methods: Tissue RNA sequencing from 39 CNS tumor tissue transcriptome samples comprising Low-Grade (LG, n=12) and High-Grade (HG, n=27) tumors was analyzed using complementary deconvolution approaches (quanTIseq, MCP-counter, EPIC, and xCell). Outputs were harmonized into a consensus TME profile summarizing overall immune infiltration, myeloid compartment activity, stromal/fibrotic programs, and immunosuppressive balance, and cross-method concordance was assessed to support robustness. Gene-set scoring (GSVA) and enrichment analysis (GSEA) quantified pathway-level programs including endothelial/angiogenesis, cancer-associated fibroblast (CAF), interferon-gamma (IFNγ) T-cell–inflamed, and antigen presentation (MHC class I/II). LG vs HG comparisons used nonparametric testing. Results: Consensus profiling demonstrated a sharp grade-associated separation in overall immune infiltration, which was higher in LG than HG (median 0.151 vs −0.108; p=0.010) with directionally concordant differences across deconvolution methods. HG tumors exhibited immunoregulatory skewing, including higher inferred regulatory T-cell abundance (Treg fraction median 0.035 vs 0.007; p=0.018) and higher Treg:CD8 ratio (median 0.147 vs 0.031; p=0.013). HG tumors also showed increased vascular/endothelial program activity (endothelial signature median −0.120 vs −0.260; p=0.032) with a trend toward increased CAF program activity (p=0.097). IFNγ T-cell–inflamed and MHC class I/II programs did not differ significantly by grade (all p≥0.37). Conclusions: Multi-algorithm consensus transcriptomic profiling identifies immune-enriched LG tumors and immune-excluded HG tumors characterized by Treg-associated immunosuppression and vascular/endothelial enrichment. These findings support TME-guided stratification of CNS tumors and motivate evaluation of combination strategies pairing immune modulation with anti-angiogenic and/or stromal-targeting approaches in HG disease.
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (17)
Shriniwas Subhash Kulkarni
Sahyadri Hospital, Pune, India
Shina Goyal
Max Super Speciality Hospital Dwarka, New Delhi, India
Vivek Agarwala
Narayana Health, NSH-Howrah & RTIICS, Kolkata, India
Stefan Schuster
Datar Cancer Genetics Europe GmbH, Bayreuth, Germany
Darshana Suresh Patil
Datar Cancer Genetics, Nashik, India
Silambarasan Maskomani
Datar Cancer Genetics, Nashik, India
Navin Srivastava
Datar Cancer Genetics, Nashik, India
Sachin Apurwa
Datar Cancer Genetics, Nashik, India
Priyanka Desale
Datar Cancer Genetics, Nashik, India
Neha Shaikh
Datar Cancer Genetics, Nashik, India
Rahul Ashok Gosavi
Datar Cancer Genetics, Nashik, India
Rajan Datar
Datar Cancer Genetics, Nashik, India
Dadasaheb Akolkar
Datar Cancer Genetics, Nashik, India
Felix Melchior
Datar Cancer Genetics Europe GmbH, Bayreuth, Germany
Ashok K. Vaid
Medanta, The Medicity, Gurugram, India
Sewanti Atul Limaye
Medical & Precision Oncology, Clinical and Translational Oncology Research, Sir HN Reliance Foundation, Mumbai, India
Kunjahari Medhi
Medanta, The Medicity, Gurugram, India